Tumor Markers Immunoassay Market (PSA, CEA, CA 125, AFP, CA 15-3, CA 19-9, CYFRA 21-1, ProGRP, SCC, CA 72-4, HE4, Others)

 
   Single User - $2,995
   Site License (one location, 10 users) - $4,495
   Corporate License - $5,990



Loading...
Published Jan 8, 2018 | 134 Pages | Pub ID: KLI15566365

Tumor Markers Immunoassay Market (PSA, CEA, CA 125, AFP, CA 15-3, CA 19-9, CYFRA 21-1, ProGRP, SCC, CA 72-4, HE4, Others)

Immunoassays have played a role in cancer management since the 1960s with the discovery of tumor markers alpha-fetoprotein (AFP) and carcinoembryonic antigen (CEA). These two tests are still an essential part of the cancer diagnostics toolbox.

Tumor Markers Immunoassay Market provides analysis of the current global market, including the following data points:
  • Tumor Markers Immunoassay Market by Marker, 2015-2025 (PSA, CEA, CA 125, AFP, CA 15-3, CA 19-9, CYFRA 21-1, ProGRP, SCC, CA 72-4, HE4, Others, Total)
  • Tumor Markers Immunoassay Market by Region, 2015-2025 (US, EU, ROW, Total)
  • Selected Tumor Marker Immunoassays
  • Attributes of Selected Tumor Marker Immunoassays (Cancer type, Tissue analyzed, How used)
  • Selected Companies Marketing Immunoassays for Tumor Markers
Biomarkers are biological or biochemical molecules, or genetic changes, or other characteristics that can be measured, and that indicate or predict a condition, risk, or likely response. Biomarkers can be used for a range of diagnostic applications including predicting disease risk, diagnosis, predicting prognosis, identifying appropriate therapy for an individual, monitoring disease or for return of a disease, and other applications. Much of the activity in the development and use of new biomarkers is in the field of oncology, where both single biomarkers and also biomarker panels are being developed and used for a wide range of applications – assessing risk of developing cancer, screening apparently healthy individuals for cancer, diagnosis of cancer, predicting prognosis, monitoring patients including monitoring for recurrence of disease, and determining the best therapy for treatment of a patient.

For many years, diagnostic assays for cancer have had important roles in diagnosis, determining prognosis, and monitoring of cancer. Early tests for diagnosing, determining prognosis, and monitoring patients with cancer include immunoassays for tumor markers originally developed by Centocor. Fujirebio acquired Centocor Diagnostics in 1998, and Centocor Diagnostics is now called Fujirebio Diagnostics.

Researchers are continuing to try to identify and validate new tumor biomarkers, but this has proven to be a slow process. Still, biomarker assays are being developed and added to the menus of large analyzers.

Assays for these tumor markers are still widely marketed by a large number of companies. Many of these companies are profiled in Tumor Markers Immunoassay Market, including:
  • Abbott Laboratories
  • AccuBioTech Co., Ltd
  • ACON Laboratories, Inc
  • Alere, Inc
  • Alfa Scientific Designs, Inc
  • Artron Laboratories, Inc
  • Atlas Link Biotech Co., Ltd
  • Audit Diagnostics
  • Autobio Diagnostics, Co., Ltd
  • Beckman Coulter, Inc
  • Beijing Wantai Biological Pharmacy Enterprise Co., Ltd
  • Binding Site Group Ltd
  • Biocare Diagnostics Ltd
  • Biocheck, Inc
  • Biomerica
  • bioMerieux SA
  • Bioscience (Tianjin) Diagnostic Technology Co., Ltd
  • Boson Biotech Co., Ltd
  • Clarity Diagnostics, LLC
  • CTK Biotech, Inc
  • DIALAB GmbH
  • Diametra
  • DiaSorin S.p.A
  • DIAsource ImmunoAssays SA
  • DRG International, Inc
  • Fujirebio US, Inc
  • GlysBy snc
  • Gold Standard Diagnostics
  • LifeSign, LLC
  • Monobind, Inc
  • Novatec Immunodiagnostica GmbH
  • Operon
  • OraSure Technologies, Inc
  • Ortho Clinical Diagnostics
  • Polymedco, Inc
  • Qualigen, Inc
  • Randox Laboratories, Ltd
  • Roche Diagnostic Corporation
  • Siemens Healthineers
  • Syntron Bioresearch, Inc
  • Teco Diagnostics
  • Thermo Fisher Scientific, Inc
  • Tosoh Bioscience, Inc
  • Trinity Biotech plc
  • Wako Diagnostics
  • WAMA Diagnostica
In this report,  {{key}} appears {{searchResults.reportMatchCounts[value]}} times
We were unable to search inside this report.
No results matched your search criteria.

Search for an exact word or phrase by placing the word or phrase in quotation marks ("market trend"). Search for different versions or tenses of a word by placing an asterisk at the end of the word (pharma*).

Please note that your term must be at least three characters long and numbers will be blocked by the # sign.